<i>In Vivo</i> Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae
Mojgan Sabet, Ziad Tarazi, David C. Griffith
Abstract
Resistance to beta-lactams has created a major clinical issue. QPX7728 is a novel ultrabroad-spectrum cyclic boronic acid beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases developed to address this resistance for use in combination with beta-lactam antibiotics. The objective of these studies was to evaluate the activity of QPX7728 in combination with multiple beta-lactams against carbapenem-resistant Klebsiella pneumoniae isolates in a neutropenic mouse thigh infection model.
Topics & Concepts
Klebsiella pneumoniaeBeta-Lactamase InhibitorsBeta-lactamBeta-lactamaseMicrobiologyAntibioticsBETA (programming language)CarbapenemIn vivoBiologyEscherichia coliGeneBiochemistryBiotechnologyProgramming languageComputer scienceAntibiotic Resistance in BacteriaPharmaceutical and Antibiotic Environmental ImpactsAntibiotics Pharmacokinetics and Efficacy